BACKGROUND/AIMS: The study was undertaken to understand the characteristic of plasma cell leukemia (PCL) in China. METHODS: We reviewed and compared medical data of 22 primary PCL, 9 secondary PCL and 461 multiple myeloma (MM) diagnosed at our institute from January 2000 to January 2008. RESULTS: The median onset ages of primary and secondary PCL patients were 49.5 and 56 years, respectively. PCL patients presented with a low peripheral blood plasmacytosis, extensive involvement of visceral organs and poor residual bone marrow function, without severe renal insufficiency. Seventeen of twenty-one PCL patients had abnormal karyotypes, mostly complex and hypodiploid or pseudodiploid. The deletion of 13q was frequent in primary and secondary PCL (57.1 and 42.9%, respectively). There was a significant difference in survival among primary PCL, secondary PCL and MM (median 14, 2 and 37 months, respectively, p = 0.0000). CONCLUSION: Overall, primary and secondary PCL are different disorders with distinct natural histories and survival. (c) 2009 S. Karger AG, Basel.
BACKGROUND/AIMS: The study was undertaken to understand the characteristic of plasma cell leukemia (PCL) in China. METHODS: We reviewed and compared medical data of 22 primary PCL, 9 secondary PCL and 461 multiple myeloma (MM) diagnosed at our institute from January 2000 to January 2008. RESULTS: The median onset ages of primary and secondary PCL patients were 49.5 and 56 years, respectively. PCL patients presented with a low peripheral blood plasmacytosis, extensive involvement of visceral organs and poor residual bone marrow function, without severe renal insufficiency. Seventeen of twenty-one PCL patients had abnormal karyotypes, mostly complex and hypodiploid or pseudodiploid. The deletion of 13q was frequent in primary and secondary PCL (57.1 and 42.9%, respectively). There was a significant difference in survival among primary PCL, secondary PCL and MM (median 14, 2 and 37 months, respectively, p = 0.0000). CONCLUSION: Overall, primary and secondary PCL are different disorders with distinct natural histories and survival. (c) 2009 S. Karger AG, Basel.
Authors: C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah Journal: Leukemia Date: 2012-11-21 Impact factor: 11.528